News

The ‘Viladecans Against Cancer’ Association Coordinator raises 16.186 euros for stomach cancer research in IDIBELL

During the course of an open ‘paella’ that brought together seven hundred and fifty people in the Cúbic space of Viladecans, the Association Viladecans Against Cancer officially offered a 16,186 euros check to IDIBELL for the investigation of new therapies in the fight against stomach cancer, led by Dr. Núria Sala (IDIBELL-ICO). This amount brings […]

Leer más about The ‘Viladecans Against Cancer’ Association Coordinator raises 16.186 euros for stomach cancer research in IDIBELL

Researchers prove the effectiveness of a new drug to prevent the onset and the pain of chemotherapy-induced neuropathy

Peripheral neuropathy is a very common side-effect of chemotherapy and may eventually lead to early discontinuation of treatment. Collaboration between research and industry led to the identification and successful testing of a new molecule capable of preventing this neurological complication. This molecule could potentially become the first existing treatment to prevent this frequent adverse effect and improve the quality of life of cancer patients. Article citation

Leer más about Researchers prove the effectiveness of a new drug to prevent the onset and the pain of chemotherapy-induced neuropathy

A new genetic marker accounts for up to 1.4% of cases of hereditary colon cancer

Researchers from the Hereditary Cancer group of the Oncobell Program of the Bellvitge Biomedical Research Institute (IDIBELL) – Hereditary Cancer Program of the Catalan Institute of Oncology (ICO) have found a new genetic marker that would explain up to 1.4% of those inherited colon cancer cases not related to the mutations currently associated with this […]

Leer más about A new genetic marker accounts for up to 1.4% of cases of hereditary colon cancer

IDIBELL scientists identify a key regulator of the acquisition of immune tolerance to tumor cells in cancer patients

The tumoral microenvironment subverts immune cell function A key regulator of myeloid derived suppressor cells and the possibility of reverting its effects on immune fucntion Article citation

Leer más about IDIBELL scientists identify a key regulator of the acquisition of immune tolerance to tumor cells in cancer patients

Success of the “H2020 Opportunities” informative session

On September 21st, an “Oportunidades en H2020 SC1 2018-20” workshop was held in the Pau Viladiu hall of Duran i Reynals Hospital. This session was jointly organized by IDIBELL’s Research Support Office and ICO’s Research Management Unit on the occasion of the imminent opening of calls for the Work Program of the H2020 Social Challenge […]

Leer más about Success of the “H2020 Opportunities” informative session

Communiqué from the universities and research centres of Catalonia

Today, the highest representatives of the universities and research centres of Catalonia (60 institutions, representing around 90% of the university and research community) have met to assess the current situation in Catalonia resulting from the actions of the Spanish Government over the last few days. The meeting was also attended by representatives of the trade […]

Leer más about Communiqué from the universities and research centres of Catalonia

A group of lymphangioleiomyomatosis (LAM) patients attend a talk on the disease and advances

David J. Kwiatkowski, a professor of medicine at Harvard University and an oncologist specializing in thoracic oncology at Dana-Farber Cancer Institute in Boston, was responsible for explaining the advances in genetics and clinical trials being conducted to combat the disease What is LAM?

Leer más about A group of lymphangioleiomyomatosis (LAM) patients attend a talk on the disease and advances
Scroll to Top